Novanta's Q1 results displayed notable revenue and bookings beats, driving an 11% stock gain as underlying demand across advanced surgery, robotics, and precision manufacturing showed clear acceleration.

• Reported revenue grew 10% year-over-year with 3% organic growth, accelerating from the prior quarter.
• Bookings surged 37% year-over-year, yielding a book-to-bill ratio of 1.10, indicating ongoing momentum.
• Adjusted EBITDA increased 14%, with margin expansion of 70 basis points, alongside a 9% rise in adjusted diluted EPS.
• Operating cash flow rose 63% year-over-year, with cash flow conversion exceeding 200% of net income.
• Double-digit growth persisted in Advanced Surgery and medical consumables; Robotics & Automation bookings jumped 50%, and Precision Manufacturing returned to mid-single-digit revenue growth.